By Lina carolina 
Researchers at Stanford Medicine have made a significant breakthrough in understanding the fundamental drivers of breast cancer aggressiveness and recurrence by identifying three broad genomic categories that underpin distinct tumor subgroups. This novel classification, based on early-established structural variations in DNA, including gene amplifications and the presence of extrachromosomal DNA (ecDNA), offers a more precise way to predict patient outcomes and guide therapeutic strategies. The findings, published in the prestigious journal Nature, have the potential to revolutionize how breast cancer is diagnosed, treated, and monitored, promising earlier and more targeted interventions for patients.
The research, spearheaded by Christina Curtis, PhD, a professor of oncology, genetics, and biomedical data science at Stanford, delves into the complex genomic architecture of breast tumors. For years, the medical community has classified breast cancers based on the presence or absence of specific protein receptors, such as estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). While this traditional classification has been instrumental in guiding treatment, it has limitations in predicting the long-term behavior of certain tumors, particularly their propensity for recurrence years after initial diagnosis.
A Deeper Dive into Genomic Subtypes
Dr. Curtis and her team’s work builds upon a decade of research aimed at unraveling the evolutionary pathways of aggressive breast tumors. Their earlier studies, employing machine-learning techniques to analyze DNA and RNA sequences, had already identified 11 clinically significant subgroups of breast cancer, far exceeding the number identified by receptor expression alone. These subgroups exhibited varied prognoses, but the underlying genomic mechanisms driving these differences remained elusive.
A pivotal moment in their research came with the observation that even in the lowest-risk groups of estrogen-receptor positive breast cancer patients who had undergone extensive hormone therapy, recurrences continued to occur years later. This persistent threat prompted the researchers to investigate whether their defined subgroups could offer a more refined risk stratification.
In 2019, a landmark study by Curtis and colleagues demonstrated that combining receptor status with their subgroup classification could effectively predict which hormone-receptor positive tumors were likely to recur long after initial treatment. This research highlighted four of the eight ER-positive subgroups as having a significantly higher likelihood of returning even 10 to 20 years post-diagnosis. Alarmingly, this elevated recurrence risk, observed in approximately a quarter of women with hormone-receptor positive, HER2-negative breast tumors, approached the levels seen in HER2-positive cancers before the advent of targeted therapies like trastuzumab (Herceptin).
Furthermore, this refined classification showed promise in identifying triple-negative breast cancer patients who were unlikely to experience recurrence beyond five years, as well as those at higher risk. This ability to stratify patients allows for more personalized treatment decisions, enabling physicians to identify individuals who might benefit from aggressive early intervention and intensive long-term monitoring, while also sparing others from potentially debilitating treatments they may not require.
The Genomic Architecture: Unveiling Three Core Categories
Despite these advancements, the fundamental biological drivers behind these differential risks remained a critical question. "We wanted to take a step back," Dr. Curtis explained in a statement. "Each of the four higher risk subgroups has copy number events—duplications or amplifications of specific oncogenes involving different regions of the genome. These patterns of genomic copy number change were similar to that seen in HER2-positive disease. If we look at these tumors in an unbiased way and deconstruct these different types of mutations, what could we learn about their processes that give rise to these characteristic events? Would we discover something different?"
To address this, the Stanford team embarked on an extensive analysis of the genomic architecture—the intricate network of mutations and structural variations within a cancer cell’s DNA—of nearly 2,000 breast tumors across various stages, from early-stage ductal carcinoma in situ to advanced metastatic disease. This comprehensive genomic profiling enabled them to categorize the tumors into three distinct groups based on unique patterns of genomic abnormalities.
The first group, characterized by complex but localized amplifications of cancer-associated genes and the presence of extrachromosomal DNA (ecDNA) rich in oncogenes, strongly overlapped with both the high-risk hormone-receptor positive subgroups and the HER2-positive subgroup. EcDNA, small circles of DNA independent of the main chromosomes, has recently been implicated as a potent driver of cancer growth and evolution, often bypassing normal cellular regulatory mechanisms. This finding is particularly striking as it reveals a shared genomic vulnerability between molecular subtypes that are traditionally treated differently in the clinic.
The second group encompasses triple-negative breast cancers. These tumors exhibit widespread genomic instability, accumulating alterations across the entire genome. A subset of these also displays deficiencies in their DNA repair mechanisms, a characteristic that renders them vulnerable to further damage. "The whole genome shows scars," Dr. Curtis noted. "It’s not limited to particular oncogenes."
The third group comprises the "garden-variety" hormone-receptor positive, HER2-negative breast cancers with typically lower risks of recurrence. These tumors generally possess relatively stable genomes, with fewer and more localized structural variations.
Early Origins, Enduring Impact
A critical revelation from this study is that these defining structural variations are established very early in the tumor’s development, often decades before diagnosis. Furthermore, these early genomic alterations are maintained throughout the progression of the disease, including metastasis. This enduring influence underscores the importance of intervening at the earliest possible stages of cancer development.
The researchers also found that these genomic categories correlate with how immune cells interact with and respond to the tumor. This interplay between the tumor’s genomic landscape and the host immune system is a burgeoning area of cancer research and could open new avenues for immunotherapy.
Implications for Targeted Therapies and Early Intervention
The implications of this research are far-reaching, offering a roadmap for the development of novel, targeted therapeutic interventions. For instance, existing drugs designed to target impaired DNA repair pathways in patients with BRCA1 and BRCA2 mutations might also prove beneficial for the approximately 13% of patients with ER-positive breast cancers exhibiting DNA repair deficiencies.
Tumors driven by focal amplifications and ecDNA could be vulnerable to compounds that specifically target these oncogene drivers or the replication stress they induce. Moreover, understanding the fundamental mutational processes that propagate these genomic alterations could lead to entirely new therapeutic strategies aimed at disrupting these pathways.
"These early, sometimes catastrophic mutational events happen decades prior to the diagnosis of the tumor, emphasizing opportunities for earlier interventions," Dr. Curtis stated. "Despite the complexity of their genomes, there are constraints and only so many evolutionary paths for a tumor to follow. We now have an understanding of how and when these complex alterations arise and their accompanying vulnerabilities."
This robust classification system has the potential to refine patient stratification, enabling physicians to precisely identify individuals most likely to benefit from aggressive early treatment, thereby improving survival rates and reducing the likelihood of recurrence. Conversely, it could also help identify patients for whom less aggressive treatment approaches are safe and effective, minimizing the burden of unnecessary toxicity.
A Call for Biomarker Development and Proactive Care
The findings strongly advocate for the development of robust biomarkers that can accurately assess these genomic signatures at the time of diagnosis. Such biomarkers would empower clinicians to make more informed decisions regarding treatment intensity and duration, moving beyond broad categorization to highly personalized therapeutic plans.
The research, supported by grants from the National Institutes of Health and the Breast Cancer Research Foundation, represents a significant leap forward in our understanding of breast cancer biology. It highlights that the fate of a tumor—its aggressiveness and its propensity for recurrence—is often predetermined by fundamental structural variations established early in its genesis. By deciphering these "born to be bad" genomic blueprints, the Stanford team is paving the way for a future where breast cancer is not only more effectively treated but also more reliably prevented from returning. The emphasis on early intervention, informed by a deeper understanding of genomic architecture, offers renewed hope for improved outcomes and a reduced burden of disease for countless patients worldwide.
